诺华CEO：正研究针对美国市场的降价方案 维持中期营收增长预期

Core Viewpoint - Novartis is preparing to propose a price reduction plan to President Trump by the end of this month, aiming to address the price disparity of drugs between the U.S. and other industrialized countries [1] Group 1: Financial Outlook - Novartis maintains its revenue growth forecast of 5% from 2024 to 2029, with profit growth expected to outpace revenue growth [1] Group 2: Strategic Preparations - The company has adequately prepared for the 15% tariff imposed by the U.S. on drugs imported from the EU, having significantly increased its inventory in the U.S. to sustain operations until mid-2026 [1]